Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Topical tofacitinib is effective and safe for treating alopecia areata.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Isotretinoin shrinks sebaceous glands without affecting hair or skin color, unlike etretinate.

Combining a 675 nm laser with isotretinoin improves acne treatment results.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Retinoids may improve hair growth in androgenic alopecia when used with other treatments.

Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

The FDA approved a new Pfizer drug for hair loss in teens.

Topical tofacitinib shows promise as a future treatment for alopecia areata.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

Topical tretinoin effectively treats acne and photoaging, with potential for other skin conditions, but more research is needed.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Low-dose isotretinoin and erythromycin effectively treated hair loss in two young sisters.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Roaccutane can cause severe liver damage.